Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 2
1994 1
1999 1
2001 1
2003 1
2004 1
2005 2
2006 3
2007 5
2008 5
2009 6
2010 2
2012 2
2016 3
2017 4
2018 2
2019 1
2020 2
2021 1
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. Hauser SL, et al. Among authors: panzara m. N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383. N Engl J Med. 2008. PMID: 18272891 Free article. Clinical Trial.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. Among authors: panzara ma. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Free article. Clinical Trial.
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC). LaRocca NG, et al. Among authors: panzara m. Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Mult Scler. 2018. PMID: 28799444 Free PMC article. Review.
Evaluating human T cell receptor gene expression by PCR.
Gussoni E, Panzara MA, Steinman L. Gussoni E, et al. Among authors: panzara ma. Curr Protoc Immunol. 2001 May;Chapter 10:10.26.1-10.26.14. doi: 10.1002/0471142735.im1026s22. Curr Protoc Immunol. 2001. PMID: 18432691 Review.
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
Baker DP, Pepinsky RB, Brickelmaier M, Gronke RS, Hu X, Olivier K, Lerner M, Miller L, Crossman M, Nestorov I, Subramanyam M, Hitchman S, Glick G, Richman S, Liu S, Zhu Y, Panzara MA, Davar G. Baker DP, et al. Among authors: panzara ma. J Interferon Cytokine Res. 2010 Oct;30(10):777-85. doi: 10.1089/jir.2010.0092. J Interferon Cytokine Res. 2010. PMID: 20836711 Review.
More on melanoma with transdifferentiation.
Panzara MA, Bozic C, Sandrock AW. Panzara MA, et al. N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089. N Engl J Med. 2008. PMID: 18596284 No abstract available.
Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease.
Claassen DO, Corey-Bloom J, Dorsey ER, Edmondson M, Kostyk SK, LeDoux MS, Reilmann R, Rosas HD, Walker F, Wheelock V, Svrzikapa N, Longo KA, Goyal J, Hung S, Panzara MA. Claassen DO, et al. Among authors: panzara ma. Neurol Genet. 2020 May 14;6(3):e430. doi: 10.1212/NXG.0000000000000430. eCollection 2020 Jun. Neurol Genet. 2020. PMID: 32548276 Free PMC article.
47 results